Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2011 April;52(2) > The Journal of Cardiovascular Surgery 2011 April;52(2):261-70

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES  CARDIAC SECTION 

The Journal of Cardiovascular Surgery 2011 April;52(2):261-70

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Heparin- and basic fibroblast growth factor-incorporated degradable stent: comparison with traditional transmyocardial revascularization

Wei Zhang G. 1, Liu X. C. 1, 2, 3, Luan Mphil Y. 3, Zhao J. 3, Shi R. Fang 2, Bin Zhao X. 2, Liu T. J. 4, Lü F. 4, Yang Q. 5, He G. W. 2. 5. 6

1 Tianjin Medical University, Tianjin, China; 2 TEDA International Cardiovascular Hospital, Medical College, Nankai University, Tianjin, China; 3 Peking Union Medical College, Beijing, China; 4 Molecular Design Laboratory, Institute of Biomedical Engineering, Peking Union Medical College, Beijing, China; 5 Department of Surgery, Chinese University of Hong Kong, Hong Kong SAR, China; 6 Providence Heart and Vascular Institute, Albert Starr Academic Center, Department of Surgery, Oregon Health and Science University, Portland, OR, USA


PDF


AIM: We have recently developed a novel method transmyocardial drilling revascularization (TMDR) combined with heparinized bFGF-incorporating degradable tubular stent implantation to revascularize ischemic myocardium. The aim of the present study was to compare the effect of this new method on left ventricular (LV) remodeling and global function to traditional transmyocardial revascularization (TMR) in acute myocardial ischemia.
METHODS: Eighteen miniswine underwent ligation of the left anterior descending (LAD) at the mid-third and were divided into three groups (N.=6 in each group): no treatment (control), TMDR (T), and TMDR+stent implantation (TS) groups. Two channels with 3.5 mm in diameter were established (T and TS groups), followed by implantation of two stents (TS group). LV function, myocardial perfusion, expression of von Willebrand factor (vWF), transforming growth factor-β3 (TGF-β3), vascular endothelial growth factor (VEGF), interleukin-1beta (IL-1β), vascular density, and histologic and morphologic analyses were evaluated at different time-points.
RESULTS: Six weeks post-treatment, there were no differences between T and control groups. TS group showed significant improvement compared to T group as to: expressions of TGF-β3, VEGF, vWF and IL-1β (P<0.001), neovascular density (2 561±391 vs. 6 201±443 pixels/hpf, P<0.001), myocardial viability (18 913±2 775 vs. 94 800±14 076 pixels/hpf, P<0.001), and dp/dtmax (1 735±161 vs. 2 242±223 mmHg/s, P<0.001), Further, there were significant decreases in changes of Mass Defect Percent (2.05±0.22% vs. -1.79±0.45%, P<0.001) and LV end diastolic volume (164.83±10.74 vs. 147.00±7.32 mL, P=0.048) in the TS group.
CONCLUSION: TMDR and stent implantation is more effective in enhancement of myocardial viability, improvement of global LV function, and attenuation of LV remodeling than TMDR.

top of page